Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-3764
Abstract: Background: RXC004, a potent and selective porcupine (PORCN) inhibitor, is being investigated in a safety and tolerability study in cancer patients with solid tumours (CT 2017-000720-98). In addition to the tumour targeting role of RXC004… read more here.
Keywords: porcupine; inhibitor; rxc004; pre clinical ... See more keywords